Tumor-Infiltrating Lymphocyte Therapy: A Powerful Treatment Option
One of the newest and most significant developments in oncology is Tumor-Infiltrating Lymphocyte Therapy, or TIL, approved by the FDA in February, 2024, following years of promising research.
The Melanoma & Skin Cancer Institute serves as an Advanced Treatment Center (ATC) for melanoma and is one of the few centers in the state of Colorado to provide TIL therapy as a treatment option for patients.
We work closely with our hospital partners to provide timely access to TIL and other cutting-edge cellular therapeutic strategies for the treatment of melanoma. Our focus on treating melanoma, as well as our dedication to research, allows The Melanoma & Skin Cancer Institute to provide TIL therapy both as a standard of care treatment and via clinical trials which can provide multiple benefits to the patient over that of standard of care.
TIL is a very intensive therapy, which can be more challenging to implement the longer a patient has been on prior treatment, so it is especially important to reach out for a consultation early if you have a melanoma diagnosis and are considering TIL therapy.
If you, a loved one, or one of your patients has a skin cancer diagnosis, you can reach out to The Melanoma & Skin Cancer Institute to book an initial consultation at 720-316-8091 or info@theskincancerinstitute.com.
Every consultation is in-depth, personalized, and includes Dr. Ryan Weight, ensuring that your treatment plan encompasses the best care for you and your condition.
What is Tumor-Infiltrating Lymphocyte Therapy?
One of the primary ways that our bodies fight cancerous tumors is through naturally occurring T cells, a subset of our innate immune system. Through the TIL process, T cells that have already infiltrated a tumor are harvested via a surgical procedure, expanded over several weeks to number in the billions, reinfused to the patient, and activated to recognize and eliminate tumors throughout the body.
TIL began as advanced therapy for the treatment of melanoma, and given its positive response rate, it is being studied as a treatment for other types of cancer as well.
It is important to know that TIL is an intensive treatment, and is not necessarily the best choice for every person or every cancer.
Individualized care from an experienced oncology team like The Melanoma & Skin Cancer Institute will help guide patients who are considering TIL (amidst many other treatment options) on the appropriate timing of these therapies and create a tailored plan for each person.
